This project will examine the effects of lymphatic vessel growth and remodeling on the severity of lung inflammation. Effects of changes in lymphatics on lung function and inflammatory responses are poorly understood and offer new therapeutic strategies. The project will determine the mechanisms of development and consequences of lymphatic vessel abnormalities in lung inflammation, assess changes in severity and susceptibility to subsequent inflammatory insults, and explore novel strategies for preventing, eliminating, or normalizing the abnormalities.
Specific Aim #1 builds on evidence that lymphatics grow and undergo remodeling in sustained inflammation, and impaired fluid and cell flux through abnormal lymphatics can exaggerate edema and alter inflammatory responses. Yet, expansion of a more normal lymphatic network can reduce inflammatory responses by improving tissue fluid drainage and immune cell traffic. New mouse models and complementary technologies will be exploited to address these issues. We will first test the hypothesis that lymphatic growth or remodeling can influence inflammatory responses in the lung. The approach will be to compare the mechanisms and consequences of remodeling of lung lymphatics in three mouse models recently found to have robust but very different changes in lymphatics. A new transgenic mouse model, where non- inflammatory growth of lymphatics in otherwise normal airways and lung is driven by overexpression of VEGF- C, will be compared to models where lymphatic growth accompanies lung inflammation. The goals are to identify factors that drive lymphatic remodeling and distinguish abnormalities in lymphatics that exaggerate inflammation from changes that reduce inflammation.
Specific Aim #2 builds on evidence that, unlike new blood vessels, new lymphatics usually do not regress when inflammation resolves and influence subsequence inflammatory responses. Pathways that promote lymphatic endothelial cell survival have been identified in recent years. These are potential targets for eliminating abnormal lymphatics. Here, we will test the hypothesis that abnormal lymphatics that persist after lung inflammation resolves can be eliminated or normalized by blocking pathways that promote endothelial cell survival. Strategies that prevent lymphatic growth (prevention models) will be compared to approaches that eliminate lymphatics (reversal models) or normalize lymphatics (normalization models). The effectiveness of blocking VEGFR-2 and VEGFR-3 signaling will be compared to effects of blocking mTOR or other pathways that support endothelial cell survival. Together, the results will provide mechanistic insights into the contribution of abnormalities in lung lymphatics to the severity of asthma, bronchitis, pneumonia, and other lung disease accompanied by sustained inflammation.

Public Health Relevance

This project will examine the effects of lymphatic vessel growth and remodeling on the severity of lung inflammation by determining the mechanisms of development and consequences of lymphatic vessel changes. Studies will also assess the influence of changes in lymphatics on the severity of inflammatory responses and will explore strategies for preventing, reversing, or normalizing lymphatic abnormalities. The results will provide mechanistic insight into the contribution of lymphatic vessel abnormalities to the severity inflammatory lung disease.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL127402-03
Application #
9230265
Study Section
Respiratory Integrative Biology and Translational Research Study Section (RIBT)
Program Officer
Xiao, Lei
Project Start
2015-04-01
Project End
2019-02-28
Budget Start
2017-03-01
Budget End
2018-02-28
Support Year
3
Fiscal Year
2017
Total Cost
$554,596
Indirect Cost
$204,693
Name
University of California San Francisco
Department
Anatomy/Cell Biology
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94118
Ma, Qiaoli; Dieterich, Lothar C; Ikenberg, Kristian et al. (2018) Unexpected contribution of lymphatic vessels to promotion of distant metastatic tumor spread. Sci Adv 4:eaat4758
Kim, Minah; Nitschké, Maximilian; Sennino, Barbara et al. (2018) Amplification of Oncolytic Vaccinia Virus Widespread Tumor Cell Killing by Sunitinib through Multiple Mechanisms. Cancer Res 78:922-937
Nitschké, Maximilian; Bell, Alexander; Karaman, Sinem et al. (2017) Retrograde Lymph Flow Leads to Chylothorax in Transgenic Mice with Lymphatic Malformations. Am J Pathol 187:1984-1997
Shepherd, Joanna; Fisher, Matthew; Welford, Abigail et al. (2017) The protective role of sphingosine-1-phosphate against the action of the vascular disrupting agent combretastatin A-4 3-O-phosphate. Oncotarget 8:95648-95661
Baluk, Peter; Yao, Li-Chin; Flores, Julio C et al. (2017) Rapamycin reversal of VEGF-C-driven lymphatic anomalies in the respiratory tract. JCI Insight 2:
Korhonen, Emilia A; Lampinen, Anita; Giri, Hemant et al. (2016) Tie1 controls angiopoietin function in vascular remodeling and inflammation. J Clin Invest 126:3495-510
Kim, Minah; Allen, Breanna; Korhonen, Emilia A et al. (2016) Opposing actions of angiopoietin-2 on Tie2 signaling and FOXO1 activation. J Clin Invest 126:3511-25
Huang, Jennifer L; Woolf, Adrian S; Kolatsi-Joannou, Maria et al. (2016) Vascular Endothelial Growth Factor C for Polycystic Kidney Diseases. J Am Soc Nephrol 27:69-77
Bose, Oishee; Baluk, Peter; Looney, Mark R et al. (2015) Mast cells present protrusions into blood vessels upon tracheal allergen challenge in mice. PLoS One 10:e0118513
Le, Catherine T K; Laidlaw, Grace; Morehouse, Christopher A et al. (2015) Synergistic actions of blocking angiopoietin-2 and tumor necrosis factor-? in suppressing remodeling of blood vessels and lymphatics in airway inflammation. Am J Pathol 185:2949-68

Showing the most recent 10 out of 16 publications